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1. Introduction 
Sarcoidosis is a multisystem disorder of unknown cause. It commonly affects young and 
middle-aged adults and frequently it presents with bilateral hilar lymphadenopathy, 
pulmonary infiltration, ocular and skin lesions. Other organs may also be involved. The 
diagnosis is established when clinicoradiological findings are supported by histological 
evidence of noncaseating epitheloid cell granulomas. Granulomas of known causes and 
local sarcoid reactions must be excluded. Frequently observed immunological features are 
depression of cutaneous delayed-type hypersensitivity and increased CD4/CD8 ratio at the 
site of involvement. Circulating immune complexes along with signs of B-cell hyperactivity 
may also be detectable. The course and prognosis may correlate with the mode of the onset 
and the extent of the disease. An acute onset with erythema nodosum or asymptomatic 
bilateral hilar lymphadenopathy usually heralds a self-limiting course, whereas an insidious 
onset, especially with multiple extrapulmonary lesions, may be followed by relentless, 
progressive fibrosis of the lungs or other organs. Corticosteroids relieve symptoms, 
suppress inflammation and granuloma formation (Grutters et al., 2009). Sarcoidosis is the 
most frequently observed interstitial lung disease of unknown origin in Europe (Müller-
Quernheim, 1998). In young adults, pulmonary sarcoidosis is the second most common 
respiratory disease after asthma (Rothkrantz-Kos, 2003). 
The reported prevalence and presenting symptoms of sarcoidosis vary significantly by sex, 
racial group, and country. The true prevalence of the disease is difficult to assess because a 
lot of patients are asymptomatic. Estimation of radiographic population screening 
programmes indicates a global prevalence of 10-40 per 100 000 and an incidence of 10 per 
100 000. The incidence appears to be higher in Northern European countries, Japan and 
African - Americans (Dements, 2001).  
Sarcoidosis is a granulomatous disorder resulting from an uncontrolled cell-mediated 
immune reaction. Following recognition of unknown antigens, the accumulation of 
immunocompetent cells in the lungs, i.e. alveolitis, occurs. Although lung parenchyma 
normally contains only a few lymphoid elements, lymphocyte populations are strikingly 
compartmentalized in air spaces and interstitium in sarcoidosis. The infiltration of activated 
CD4 positive T-cells represents the immunological hallmark of sarcoidosis. However, many 
types of other immune cells, such as macrophages, are involved in the inflammatory 
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response of the disorder. In the lung, this accumulation in both air spaces and interstitium 
(alveolitis) precedes and accompanies the development of granulomas (Semenzato, 2005). 
Sarcoid granulomas are immune granulomas resulting from a specific cell-mediated 
immune response to an antigenic antigen. The granulomas of sarcoidosis are well-formed, 
compact aggregates. They usually are of varying age, ranging from highly cellular lesions to 
collections with diminishing cellularity, some fibrosis and progressive hyalinization. Two 
characteristic zones can be seen in a typical, well-developed sarcoid granuloma: 1) a central 
zone or follicle, which is tightly packed with cells composed primarily of macrophages, 
multinucleated giant cells and epitheloid cells; 2) a peripheral zone consisting of a collar of 
loosely arranged lymphocytes, monocytes and fibroblasts. Although many microscopic 
features may suggest sarcoidosis, the epitheloid granulomas, especially in their earlier 
stages, are indistinguishable from those of other idiopathic granulomatous disorders or even 
granulomatous disorders of known origin, such as berylliosis, tuberculosis or 
hypersensitivity pneumonitis (Müller-Quernheim, 1998). 
Sarcoidosis is a worldwide disease with a lifetime incidence rate of 0.85-2.4 %. It generally 
affects 25-40-year-old people. The clinical phenotype of sarcoidosis can be extremely diverse 
in terms of presentation, involved organs, duration and severity. Lung involvement is 
present in 86-92 % of cases according to the chest X-ray, alone or in association with 
extrapulmonary localizations in about 50 % of cases (Nunes, 2005). International pulmonary 
registries have illustrated differences in the presentation of sarcoidosis in different countries: 
in Asia the majority of cases presented with a radiological stage I, and a positive tuberculin 
skin test was found more frequently than in other countries. However, erythema nodosum 
has not been reported among the Japanese, is rare among African-Americans, it is the 
presenting symptom in 18% of cases in Finland and occurs in about 30% of British 
sarcoidosis patients (Dements, 2001). 
Clinical features of sarcoidosis are varied. It may manifest as an acute form (Löfgren’s 
syndrome), chronic sarcoidosis or asymptomatic disease that may be found accidentally. 
However, even an acute form (e.g. erythema nodosum and joint pain) of disorder, which is 
the most typical clinical feature of sarcoidosis, is a nonspecific one (Bourke, 2006). 
There are five radiologic stages (forms) of intrathoracic changes of sarcoidosis: stage 0, 
normal chest radiograph; stage 1, only lymphadenopathy; stage 2, lymphadenopathy with 
parenchyma infiltration; stage 3, only parenchymal disease; stage 4, pulmonary fibrosis 
(Koyama, 2004). Sarcoidosis may present at any stage. However, a great variation of 
radiologic appearance in each stage has been noticed. Radiographic features of sarcoidosis 
may be atypical, especially in older patients (Conant, 1988). Pulmonary sarcoidosis 
radiologically may be indistinguishable from tuberculosis, lymphangitic carcinomatosis, 
pulmonary metastases or metastatic lymphadenopathy (Heo, 2005; Kaira, 2007; Thomas 
2008). Furthermore, subtle radiologic changes in sarcoidosis (e.g. presence of subpleural 
micronodules or mild intrathoracic lymphadenopathy) may be similar to those present in 
healthy adults, especially smokers and/or residents of urban areas (Remy-Jardin, 1990). 
Histological features of the disease are varied (Rosen, 1978). Non-necrotising granuloma, a 
hallmark of morphologic appearance of the disease, is not unique for sarcoidosis. The 
granulomas in tuberculosis, extrinsic allergic alveolitis (hypersensitivity pneumonitis) and 
chronic beryllium disease are often identical to those of sarcoidosis (Williams, 1967; Popper, 
1999). Even if the pathologic diagnosis of sarcoidosis is confirmed by biopsy, this may not 
confirm that all the lesions appear because of sarcoidosis (Kaira, 2007). Usage of needle 
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aspirate, either transbronchial or percutaneous, provides support but never an absolute 
proof of diagnosis (Baughman, 2000). Sarcoid-like reactions have been reported to be 
associated with carcinoma and lymphoma (Brincker, 1986; Laurberg, 1975; Tomimaru, 2007). 
Bronchoalveolar lavage (BAL) is a method of sampling fluid and cells from a large area of 
the lung tissue by instilling and aspirating saline via a bronchoscope wedged in bronchi. 
BAL as a method of sampling cells is very useful in the diagnosis and differential diagnosis 
of sarcoidosis (Drent, 1993; Welker, 2004). High lymphocytosis and CD4/CD8 ratio in 
bronchoalveolar lavage fluid (BALF) are the main features of sarcoidosis (Poulter, 1992). In 
patients with a clinical picture typical for sarcoidosis, an elevated CD4/CD8 ratio in BAL 
fluid may confirm the diagnosis and obviate the need for biopsy (Costabel, 2001; Kvale, 
2003). However, CD4/CD8 ratio in BALF is highly variable (Kantrow, 1997). BALF cell 
patterns, including CD4/CD8 ratio are related to radiographic stage, clinical symptoms of 
sarcoidosis and previous empiric treatment with corticosteroids. Optimal cutoff point for 
CD4/CD8 ratio is different in various manifestations of sarcoidosis (Danila et al., 2008, 
2009).  
Diagnosis of sarcoidosis requires a compatible clinical and radiologic picture. However, 
there are no specific diagnostic tests and sarcoidosis is therefore a diagnosis of exclusion 
(Boer, 2010). The diagnosis of sarcoidosis must always be based on summation of clinical 
and radiological symptoms, results of BALF examination and other findings, which include 
data of histological examination of the lung or lymph node biopsy material if necessary.  
In this chapter the diagnostic role of bronchoalveolar lavage and other sampling methods 
(including endobronchial biopsy, bronchoscopic lung biopsy, transbronchial lymph node 
biopsy and mediastinoscopy) in various clinical situations are discussed.  
2. Bronchoalveolar lavage 
2.1 History of bronchoalveolar lavage 
Bronchoalveolar lavage was first used at Yale in 1922 in the management of phosgene 
poising. This approach has been extended to cystic fibrosis and alveolar proteinosis. In 1961, 
Myrvik showed how this simple lavage procedure could be used in rabbits to obtain lung 
macrophages. This seminal observation spawned new discipline, pulmonary cell biology 
(Gee & Fick, 1980). With the introduction in the mid-1960’s of the design of the fiberoptic 
bronchoscope into clinical medicine by S. Ikeda, bronchoalveolar lavage was widely used 
for clinical investigations and diagnostic purposes (Zizel & Müller-Quernheim, 1998). 
Bronchoalveolar lavage was adapted to fiberoptic bronchoscopy by Reynolds and Newball 
in 1974 (Winterbauer et al., 1993). Bronchoscopy and lavage procedure have been a great 
stimulus for lung research to have access to normal and disease-affected airways and 
alveolar surfaces for direct samples (Reynolds, 1992). The observation of characteristic 
changes in the cytology of the BAL fluid in interstitial lung diseases were first reported by 
Hunninghake and Crystal in 1981 (Müller-Quernheim, 1998). With the widespread use of 
fibreoptic bronchoscopy for diagnostic evaluation of patients with interstitial lung diseases, 
bronchoalveolar lavage has also become part of the procedure (Reynolds, 1992). 
2.2 Technique of bronchoalveolar lavage 
After the fiberoptic bronchoscope has been inserted and the search for abnormalities in the 
respiratory tract is complete, the tip of the bronchoscope should be advanced into the 
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desired bronchus as far as possible until well wedged. Biopsy and brushing should be 
avoided before BAL. The right middle lobe or the lingula of the left lung are the preferred 
sites for BAL (Emad, 1997). From these lobes, almost 20 % of more fluid and cells are 
recovered than from the lower lobes. However, in cases of predominant infiltrates in other 
lobes (e.g. upper lobe), bronchaolaveolar lavage should be done in these lobes or multiple 
lung segments (Cantin et al., 1983; Ziora et al. 2001). 
The fluid used to perform bronchoalveolar lavage is isotonic 0,9 % NaCl solution suitable 
for intravenous use. Saline fluid is instilled through the working channel of the fiberoptic 
bronchoscope as a bolus with syringe with aliquots of 20 ml to 100 ml. The volume infused 
ranges from 100 ml to 300 ml. Overall, the amount of BAL fluid collected is about 40-60 % of 
the volume instilled (Klech & Pohl, 1989). The first neutrophil-rich aliquot, which contains 
the airways sample, is usually excluded from analysis of BALF differential cell count. 
The information about cell types obtained in volumes of 100-250 ml is comparable, 
supposedly that cell populations obtained from volumes excess of 120 ml will not add to 
diagnostic accuracy. In most patients with sarcoidosis lavage at one site gives sufficient 
clinical information (Klech & Pohl, 1989; Winterbauer et al., 1993).       
After measuring the recovered volume and performing total cell counts, the normal method 
of processing the cells from the BALF for differential counting is to prepare cytospins. The 
differential counts are assessed by viewing with a light microscope and counting at least 
300-500 cells (Klech & Pohl, 1989). Lymphocyte subsets (CD4 and CD8) are evaluated 
usually using flow cytometry.      
2.3 Cellular components of bronchoalveolar lavage fluid in healthy persons  
The alveolar macrophages constitute the largest cell population in BALF, about 80-95 % of 
total recovered cells. Lymphocytes are the second major cell population in BALF .Other cells 
found in lavage fluid include neutrophils, occasional eosinophils, basophils and mast cells. 
For practical reasons the following percentages can be expected as normal within 
nonsmokers: lymphocytes < 20 %, neutrophils < 5 %, eosinophils < 0.5 %. T lymphocytes are 
the main lymphocytes, and the ratio of T-helper to T-suppressors (CD4/CD8) is 
approximately 1.0-3.5. Smokers usually have a decreased percentage of lymphocytes and 
decreased CD4/CD8 ratio (Klech & Pohl, 1989; Zizel & Müller-Quernheim, 1998). 
2.4 Cellular components of bronchoalveolar lavage fluid in sarcoidosis 
Bronchoalveolar lavage is thought to mirror parenchymal inflammation in the interstitial 
lung diseases. In sarcoidosis BAL recovers activated lymphocytes and alveolar 
macrophages, which are the precursors of granuloma formation (Hendricks et al., 1999). A 
distinct compartmentalization to the lungs of CD4 T cells has been already found in the 
early 1980s. The characteristic finding of lung-accumulated CD4 T cells in sarcoidosis and 
resulting increase in the BAL fluid CD4/CD8 ratio has come to be a clinically important 
marker of the disease and is used for diagnostic purposes (Grunewald & Eklund, 2007). 
However, cellular components and T lymphocyte profiles are related to clinical 
presentation, radiological stage, smoking status, and previous treatment with corticosteroids 
(Danila et al., 2008, 2009). Therefore, the CD4/CD8 ratio in BAL fluid may be highly variable 
(Kantrow et al., 1997). It should be remembered that advanced sarcoidosis may present with 
no increase in numbers of BAL fluid lymphocytes, and CD4/CD8 ratio can be normal. 
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Patients with erythema nodosum and/or arthralgia show the most marked characteristics 
of alveolitis, including increased percentages of T lymphocytes, the highest CD4/CD8 
ratios (up to 30) in BALF samples (Ward et al., 1989; Drent et al., 1993). However, 
asymptomatic sarcoid patients have significantly lower BAL fluid lymphocytosis and 
CD4/CD8 ratio comparing with non-treated patients with sarcoidosis-related symptoms. 
Moreover, previously corticosteroid-treated symptomatic patients have lower BALF 
lymphocytosis and CD4/CD8 ratio compared to non-treated symptomatic patients 
(Danila et al., 2009). The increase of the macrophage and neutrophil count, decrease of 
lymphocyte count and CD4/CD8 ratio with increased radiographic stage of sarcoidosis in 
BAL fluid in patients with newly diagnosed sarcoidosis have been documented (Danila et 
al., 2008). 
Spontaneous macrophage-lymphocytes rosettes (adherence of lymphocytes to alveolar 
macrophages) in BALF from active sarcoid patients have been found, probably due to active 
antigen presentation at the focus of inflammation (Reynolds, 1992). Macrophage-
lymphocyte rosettes and giant cells (elements of immune granuloma) are found more often 
in BAL fluid of symptomatic patient groups compared to asymptomatic patients (Danila et 
al., 2008). A case of severe pulmonary sarcoidosis with intact granulomas in BAL fluid was 
described in medical literature (Hendricks et al., 1999). These findings may reflect still on-
going inflammation in lung parenchyma.  
Acute onset of the disease and high CD4/CD8 ratio is associated with good prognosis. On the 
other hand, increased neutrophil counts are associated with a more advanced, chronic disease 
course, impaired lung function, poor response to corticosteroid treatment and persisting 
abnormal chest radiographs. It is supposed that an increased percentage of BAL fluid 
neutrophils and eosinophils reflect an ongoing inflammatory process, which may result in 
progressive loss of lung parenchyma (Lin et al., 1985; Dren et al., 1999; Ziegenhagen et al., 
2003). However, BALF lymphocyte count at diagnosis is not a valuable prognostic factor in 
patients with newly diagnosed sarcoidosis (Greening et al., 1984; Laviolette et al., 1991). 
Moreover, high lymphocyte count and high CD4 lymphocyte count (as percentage of 
lymphocytes) reflect an intense alveolitis at the time of the procedure, but they are not 
indicators of poor prognosis on which therapeutic decisions can be based (Verstraeten et al., 
1990) and may be a favorable prognostic factor for lung function in pulmonary sarcoidosis 
(Foley et al., 1989). 
Sarcoidosis patients may present with extrapulmonary lesions due to the multisystem 
character of the disease. In patients presenting with extrapulmonary sarcoid lesions 
interstitial pulmonary changes with or without hilar adenopathy may be present. There may 
be a normal chest X-ray film, but conclusions from roentgenographic examination may 
underestimate the alveolitis already present. Moreover, typical sarcoid changes in BAL fluid 
samples can be found even without lung field involvement shown by high-resolution 
computed tomography, for example in patients with only ocular findings (ocular 
sarcoidosis) (Hoogsteden et al., 1988; Takahashi et al., 2001).  
Cigarette smoking modifies the immunologic BAL fluid sample profile and alveolitis is 
found to be less pronounced in smokers. Smoking results in increased total cell counts, 
increased CD8 lymphocytes, and less increased CD4/CD8 ratios in the BAL fluid samples in 
sarcoid patients. CD4/CD8 ratios are lower in smoking than in non-smoking patients 
(Valeyre et al., 1988; Drent et al., 1993).    
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2.5 Clinical role of bronchoalveolar lavage in pulmonary sarcoidosis 
Several groups of investigators examined diagnostic value of the CD4/CD8 ratio of BAL 
lymphocytes for differentiating sarcoidosis from other causes of lung diseases. Costabel et al. 
reported that a ratio of 3.5 or greater had a sensitivity of 52 % and specificity of 94 % in 117 
consecutive patients with biopsy-proven sarcoidosis (Costabel et al., 1992). Winterbauer et 
al. described that a ratio of 4.0 or greater distinguished patients with sarcoidosis from 
patients with other interstitial lung diseases with a sensitivity of 59 % and a specificity of 96 
% (Winterbauer et al., 1993). Thomeer & Demedts found that a CD4/CD8 ratio of greater 
than 4.0 had a sensitivity of 55 % and a specificity of 94 % (Thomeer & Demedts, 1997). 
Welker et al. found that when the CD4/CD8 ratio is combined with lymphocyte and 
granulocyte numbers, the probability of sarcoidosis could exceed 85 % (Welker et al., 2004).  
 
Group 
Selected 
cutoff 
Sensitivity 
(95% CI), % 
Specificity 
(95% CI), % 
PPV 
% 
NPV 
% 
All patients 
3.5 
4.0 
5.0 
8.0 
10.0 
80 
76 
66 
58 
26 
90 
93 
95 
99 
100 
96 
97 
97 
99 
100 
64 
59 
50 
37 
33 
Asymptomatic 
3.5 
4.0 
5.0 
8.0 
10.0 
62 
57 
49 
21 
10 
90 
93 
97 
99 
100 
86 
89 
94 
99 
100 
68 
67 
62 
54 
51 
Symptomatic 
non-treated 
3.5 
4.0 
5.0 
8.0 
10.0 
86 
84 
81 
52 
37 
90 
93 
95 
99 
100 
92 
94 
95 
98 
100 
90 
85 
79 
61 
55 
Symptomatic 
treated 
3.5 
4.0 
5.0 
8.0 
10.0 
83 
77 
70 
50 
33 
91 
93 
96 
99 
100 
73 
77 
86 
98 
100 
94 
93 
91 
85 
83 
CI – confidence interval. PPV – positive predicted value. NPV – negative predicted value.  
Table 1. Diagnostic value of sarcoid patients’ bronchoalveolar lavage fluid CD4/CD8 ratio 
in relation to clinical symptoms (Danila et al., 2009) 
Comparable results were reported by other authors (Fireman et al., 1999). CD4/CD8 ratio of 
less than 1.0 virtually excludes the diagnosis of sarcoidosis (Winterbauer et al., 1993).  
We have found that optimal cutoff points for CD4/CD8 ratio are 3.5 and 4.0 for 
asymptomatic and symptomatic patients, respectively (Danila et al., 2009). Sensitivity of the 
optimal cutoff points (3.5 and 4.0) of CD4/CD8 ratio were lower in the asymptomatic 
patient groups compared to the symptomatic (non-treated and treated) patients. Sensitivity 
of the optimal cutoff points decreased with increased stage of sarcoidosis. The values of 
sensitivity, specificity and predicted values are presented in Tables 1 and 2. Normal BALF 
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cell counts were found in 7 % of 318 consecutive sarcoid patients with newly diagnosed 
disease. However, typical sarcoid BAL fluid cellular pattern (lymphocytosis and CD4/CD4 
>3.5) was found in 6.2 % of all control subjects. Additionally, in 3.8 % of all control subjects 
BALF CD4/CD8 ratios of more than 3.5 without lymphocytosis were found.  
Maximum value of BALF CD4/CD8 ratio for non-sarcoid subjects was 5.6, except for one 
patient with non-Hodgkin’s lymphoma of low-grade malignancy (CD4/CD4 ratio = 8.8). 
According to the world-leading expert in interstitial lung disorders Professor U. Costabel 
examination of bronchoalveolar lavage fluid may be of diagnostic value in sarcoidosis, 
obviating need of biopsy in 40-60 % of patients (Costabel, 1997). The author’s experience is 
in agreement with this statement. Having in mind that significant part of sarcoid patients, at 
least in European countries, manifested with an acute form of the disease (Löfgren’s 
syndrome of fever, erythema nodosum, arthralgias, and bilateral hilar lymphadenopathy), 
even more of the patients due to very typical clinical-radiological symptoms and signs may 
obviate need of biopsy. 
 
Group 
Selected 
cutoff 
Sensitivity 
(95% CI), % 
Specificity 
(95% CI), % 
PPV 
% 
NPV 
% 
Stage 1 
3.5 
4.0 
5.0 
8.0 
10.0 
88 
85 
78 
47 
33 
90 
92 
96 
99 
100 
94 
95 
97 
99 
100 
81 
77 
69 
52 
46 
Stage 2 
3.5 
4.0 
5.0 
8.0 
10.0 
74 
69 
57 
25 
18 
91 
92 
95 
99 
100 
84 
87 
89 
95 
100 
83 
80 
78 
67 
65 
Stage 3 
3.5 
4.0 
5.0 
8.0 
10.0 
46 
42 
34 
15 
5 
90 
92 
96 
99 
100 
59 
64 
66 
95 
100 
85 
84 
83 
80 
77 
CI – confidence interval. PPV – positive predicted value. NPV – negative predicted value.  
Table 2. Diagnostic value of sarcoid patients’ bronchoalveolar lavage fluid CD4/CD8 ratio 
in relation to a Stage (Danila et al., 2009) 
So CD4/CD8 ratio has an important role in personal diagnostic algorithms of many clinicians, 
although the best use of this test requires considerable experience in its application (Wells, 
2010).  In summary, an increased lymphocyte count with CD4/CD8 ratio > 3.5 is regarded as 
typical for pulmonary sarcoidosis, and is considered generally sufficient to secure the 
diagnosis of sarcoidosis in the appropriate clinical setting (Spagnolo et al., 2009). 
2.6 Side-effects of bronchoalveolar lavage 
One of the reasons why bronchoalveolar lavage is enjoying its general acceptance among 
scientists and clinicians is its noninvasiveness. This makes bronchoalveolar lavage possible 
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to perform in virtually all patients with few exceptions. Bronchoalaveolar lavage is a very 
safe procedure. Serious complications like significant bleeding, pneumothorax and other are 
extremely rare (Klech et al., 1992). Fever occurred some hours after BAL in about one fifth of 
all patients that underwent the procedure. Side-effects can be minimized by not exceeding 
lavage volume of 250 ml (Klech & Pohl, 1989). At the Department headed by the author only 
one serious complication of bronchoalveolar lavage (performed in a patient with 
tuberculosis) – pneumothorax, occurred during the last fifteen years. So, the rate of serious 
complications is extremely small, less than 0.1 %. Usually we do not perform BAL in 
patients with blood platelet count below 20000 / μl. Through its safety bronchoalveolar 
lavage does not raise any special ethical considerations (Rennard et al., 1992).  
3. Endobronchial biopsy 
3.1 Airway involvement in sarcoidosis 
Bronchoscopic abnormalities have been observed in up to 60 % of patients with sarcoidosis 
(Shorr et al., 2001). These include “retinalization” of mucosa from increased mucosal 
vascularity, mucosal coarseness, pallor, flat yellow mucosal plaques, wartlike excrescences, 
“bleb-like” formations, irregular mucosal thickening, ulceration, and atrophic mucosa. The 
three common findings were bronchial mucosal hyperemia or edema, distortion of the 
bronchial anatomy, and bronchial narrowing (due to extrinsic compression of airways by 
the enlarged lymphnodes, various types of mucosal involvement or airway distortion 
caused by parenchymal changes). The classic endobronchial sarcoidosis is characterized by 
mucosal islands of waxy yellow mucosal nodules, 2 to 4 mm in diameter. Bronchoscopy 
may reveal endobronchial occlusion by sarcoid granulomas in the submucosa or an 
endobronchial polyp caused by sarcoid granulomas.  Lobar, segmental, subsegmental, and 
more distal bronchi as well as bronchioles are affected more frequently than the trachea and 
main bronchi (Polychronopoulos & Prakash, 2009). Rarely, sarcoidosis manifested with 
endoluminal stenosis of proximal bronchi (Chambellan et al., 2005). The presence of 
endobronchial sarcoid lesions significantly increases the risk for airway obstruction and 
airway hyperreactivity in patients with sarcoidosis (Lavergne et al., 1999; Shorr et al., 2001). 
3.2 Technique of endobronchial biopsy 
After satisfactory anesthesia is established, the lesion is visualized, biopsy forceps are 
passed through the working channel of the fiberoptic bronchoscopy until the forceps are just 
beyond the tip of the bronchoscope. The forceps are opened, advanced into the area to be 
biopsed, and closed firmly. The forceps should be withdrawn slowly to avoid its slipping 
from the tissue. The forceps may then be withdrawn through the bronchoscope (Cortese & 
McDougall, 1994). Biopsy is taken from most prominent lesions. If bronchial mucosa seems 
normal, biopsy is usually taken from the carina of segmental, subsegmental or 
subsubsegmental bronchus. Usually from 4 to 6 biopsy samples are taken.      
3.3 Diagnostic yield of endobronchial biopsy in sarcoidosis 
Although airway appearance affects the results of endobronchial biopsy (EBB), this biopsy 
technique may demonstrate non-necrotizing granulomas even if the airways are normal on 
visual inspection. EBB resulted in diagnostic tissue in 50-70 % of cases (Puar et al., 1985; 
Shorr et al., 2001). The results of EBB correlated with airway appearance. EBB result is more 
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likely to be positive if the endobronchial mucosa is abnormal. However, a normal-appearing 
airway mucosa does not exclude the presence of granulomas. EBB is positive in 
approximately 35 % of subjects with normal airway mucosa.  Endobronchial biopsy 
increased in about 20 % in diagnostic value of fiberoptic bronchoscopy (Shorr et al., 2001). 
3.4 Side-effects of endobronchial biopsy 
Endobronchial biopsy is an extremely safe procedure. To the best of the author’s knowledge 
there are no publications addressed specifically to the side-effects to endobronchial biopsy 
in sarcoidosis. The risk of the major complications during endobronchial biopsy, such as 
significant bleeding, is extremely small when a patient’s blood platelets count is 50000 /μl or 
more. However, it should be remembered that massive or even fatal bleeding may occur 
after endobronchial biopsy in case of an abnormal bronchial artery of Dieulafoy’s disease of 
the bronchus (Sweerts et al., 1995; Werf et al., 1999; Maxeiner, 2001; Stoopen et al., 2001), 
which may appear as submucosal smooth elevated non-pulsating lesion. At the Department 
for which the author works only one massive bleeding after endobronchial biopsy 
(presumably due to abnormal located bronchial artery) occurred during the last twenty 
years. There happened no other with endobronchial biopsy associated to serious 
complications during this period. Thus, the rate of serious complications after this 
procedure is less than 0.05 %.      
4. Bronchoscopic lung biopsy 
4.1 History of bronchoscopic lung biopsy 
The ability to obtain lung tissue without subjecting a patient to an open lung biopsy is a 
major advance in diagnostic bronchoscopy. Bronchoscopic lung biopsy (also named as 
transbronchial lung biopsy) was first performed by H. Andersen in 1963, using the rigid 
bronchoscope. In 1974 first results of the BLB via the flexible bronchoscope were published 
(McDougall & Cortese, 1994). After introduction of the fiberoptic bronchoscope into clinical 
practice, bronchoscopic lung biopsy (BLB) during fibrobronchoscopy became a standard 
procedure. BLB is utilised to sample alveolar parenchyma beginning at the bronchiolar, 
noncartilaginous segment of the airway (Leslie et al., 2000). 
4.2 Technique of bronchoscopic lung biopsy 
After the inspection of the tracheobronchial tree, a bronchoscope is inserted to subsegmental 
or smaller bronchus until the wedging position. Under fluoroscopic control, biopsy forceps 
(a crocodile type biopsy forceps are usually used) are pushed forward until a peripheral 
position. The position of biopsy forceps is controled by two directions of chest fluoroscopy. 
Afterwards, the forceps are withdrawn about 2-3 cm, then opened and pushed forward. 
Usually this maneuver is repeated once or twice, and then the forceps are closed and 
withdrawn. If the patient indicates ipsilateral chest or shoulder pain then forceps are closed, 
and should be opened and withdrawn a few centimeters before closing or introducing to 
other segment or subsegment of the lung. The bronchoscope should not be removed from a 
wedge position until there is no evidence of significant bleeding. The BLB is usually 
performed after a patient‘s inhale (Zavala, 1978; McDougall & Cortese, 1994; Dierkesmann 
& Dobbertin, 1998). In the Department for which the author works for about 6 biopsies are 
performed in cases of suspected sarcoidosis. Most of the samples are of 1-3 mm in diameter. 
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4.3 Diagnostic yield of bronchoscopic lung biopsy in sarcoidosis 
The specimens obtained during bronchoscopic lung biopsy are small, but in most cases 
permit accurate histological diagnosis. Although some authors (Roethe et al., 1980) indicated 
that 10 are optimal for obtaining the diagnosis in stage I and 5 biopsies in stages II and III. 
Most investigators (Gilman & Wang, 1980; Harber, 1981, Cavazza et al., 2009) found that 3-5 
biopsies are enough when biopsy is performed by an experienced bronchoscopist.   
Bronchoscopic lung biopsy has diagnostic yield of 50 % to 97 % (Mitchell et al., 1980; Roethe 
et al., 1980; Puar et al., 1985; Leonard et al., 1997; Boer et al., 2009). Density of the 
granulomas in the lung is not uniform (Rosen et al., 1977). Rosen et al. have found that 
nongranulomatous, nonspecific interstitial pneumonitis were predominant or prominent 
histopathologic findings in 62% of 128 granuloma-containing specimens from open lung 
biopsies obtained from patients with sarcoidosis (Rosen et al., 1978). Diagnostic accuracy is 
increased when biopsy is taken from the lobes with predominant involvement by chest X-
ray or computed tomography scanning (Roethe et al., 1980; Boer et al., 2009). 
Although the rate of positive findings on BLB is high among patients with sarcoidosis who 
have radiological evidence of pulmonary infiltration, it is also high (about 60 %) among 
patients with or even without hilar lymphadenopathy whose chest radiographs show 
normal lung fields (Mitchell et al., 1980; Ohara et al., 1993). 
A generous transbronchial biopsy may show numerous compact, coalescent, non-
necrotizing granulomas embedded within hyaline collagen, i.e. features almost diagnostic of 
sarcoidosis. Frequently, however, not only bronchial but also transbronchial biopsies show 
just a tiny granuloma, or even a single giant cell or a Schaumann body, that may be enough 
for the diagnosis but require a more robust clinical support. Sarcoid granulomas, although 
classically non-necrotizing, may show necrosis. It generally consists of tiny foci of central 
fibrinoid (“rheumatoid-like”) necrosis, but rarely larger areas of fibrinoid, infarct, or 
suppurative (“Wegener-like”) necrosis may be seen (Cavazza et al., 2009). 
Two characteristic zones can be seen in a typical, well-developed sarcoid granuloma: 1) a 
central zone or follicle which is tightly packed with cells composed primarily of 
macrophages, multinucleated giant cells and epitheloid cells; 2) a peripheral zone consisting 
of a collar of loosely arranged lymphocytes, monocytes and fibroblasts. Taken alone 
granulomas do not confirm the diagnosis of sarcoidosis, since it may also occur in 
tuberculosis, lymphoma or other malignant disease, berylliosis, brucellosis, extrinsic allergic 
alveolitis, histoplasmosis, collagen disorders, and other (Müller-Quernheim, 1998). 
Specificity of noncaseating epithelioid cell granuloma in transbronchial biopsy for the 
distinction between sarcoidosis and other forms of diffuse lung disease may be high – about 
90 % (Winterbauer et al., 1993). However, specificity of noncaseating granuloma may be less 
in countries with moderate or high prevalence of pulmonary tuberculosis. Our findings 
show that the sensitivity of non-necrotizing epithelioid cell granuloma in bronchoscopic 
biopsy for the diagnosis of sarcoidosis is high (94 %), as well as the negative predictive value 
(92 %) of this type of epithelioid cell granuloma for the exclusion of sarcoidosis. However, 
the specificity of epithelioid cell granuloma without necrosis in our investigated group was 
relatively low-only 60 %. We have found a significant overlap in types of granulomatous 
inflammation between tuberculosis and sarcoidosis. Moreover, non-necrotizing granulomas 
were found in several cases of adenocarcinoma and hematological disorder (Danila & 
Žurauskas, 2008).  
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4.4 Side-effects of bronchoscopic lung biopsy 
Bronchoscopic lung biopsy is a relatively safe diagnostic method. The pneumothorax rate 
after BLB is 1-5% (Zavala, 1978; Cortese & McDougall, 1997; Becker et al., 1998; Ensminger & 
Prakash, 2006). Bleeding after the BLB for carefully selected patients is rare and not 
intensive. Life-threatening haemoptysis occurred in 2-5% of the BLB (Cortese & McDougall, 
1997; Dierkesmann & Dobbertin, 1998). Lethal outcome mostly due to the massive bleeding, 
or pneumothorax, is rare, and it occurred in 0-0.2% of the cases (Schulte & Costabel, 
1998).Uremia increased the risk of bleeding. 
In author’s institution of all the bronchoscopic lung biopsies, serious complications occurred 
in 2.6 % patients. Clinically significant pneumothorax requiring chest tube treatment 
occurred in 1.6 % patients. Non-significant pneumothorax not requiring the chest tube 
treatment occurred in 0.7% patients. Severe bleeding occurred in 1 % out of all BLBs. In all 
the cases the bleeding was stopped during the same procedure, after the bronchoscope tip in 
bronchus was occluded for several minutes (Danila et al., 2008). There was no lethal 
outcome related to BLB performed to more than 500 patients during the last fifteen years. 
5. Transbronchial needle aspiration biopsy and endosonography guided 
needle aspiration biopsy 
5.1 Standard transbronchial needle aspiration biopsy 
The history of transbronchial needle aspiration (TBNA) goes back to 1949 when Eduardo 
Schieppat presented his new technique of endoscopical puncturing mediastinal lymph 
nodes across the tracheal spur (Leonard et al., 1997). In 1978, Wang with colleagues first 
described needle aspiration of paratracheal masses. In 1979, Oho and colleagues reported 
use of the first needle adapted for the flexible bronchoscope (Midthun & Cortese, 1994). To 
obtain cytology specimens, 20–22-gauge needles are usually used, while 19-gauge needles 
are needed to obtain a “core” of tissue for histology. TBNA can be performed safely and 
successfully during routine flexible bronchoscopy under local anaesthesia. 
Selection of the proper site for needle insertion to increase diagnostic yield may be 
facilitated by reviewing the CT scan of the chest. The bevelled end of the needle must be 
secured within the metal hub during its passage through the working channel. The needle is 
advanced and locked in place only after the metal hub is visible beyond the tip of the 
working channel. The catheter can then be retracted, keeping the tip of the needle distal to 
the end of the fibrebronchoscope. The scope is then advanced to the target area and the tip 
of the needle is anchored in the intercartilaginous space in an attempt to penetrate the 
airway wall as perpendicularly as possible. With the needle inserted, suction is applied at 
the proximal port using a syringe. Aspiration of blood indicates inadvertent penetration of a 
blood vessel. In this case, suction is released, the needle is retracted and a new site is 
selected for aspiration. When there is no blood in the aspirate, the catheter is moved up and 
down with continuous suction, in an attempt to shear off cells from the mass or lymph node. 
The needle is withdrawn from the target site after the suction is released (Herth et al., 2006). 
Three to five passes in each location are recommended (Tremblay et al., 2009). Whenever 
possible, sampling of more than one nodal station is advised to increase diagnostic yield 
(Trisolini et al., 2008). 
The diagnostic yield of conventional TBNA ranges from 54 % to 90 % (Wang et al., 1989; 
Trisolini et al., 2003; Oki et al., 2007; Trisolini et al., 2008; Tremblay et al., 2009).  
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5.2 Endobronchial ultrasonography guided transbronchial needle aspiration biopsy 
The integration of ultrasound technology and flexible fibrebronchoscopy – endobronchial 
ultrasound (EBUS) enables imaging of lymph nodes, lesions and vessels located beyond the 
tracheobronchial mucosa. Recently real-time EBUS-TBNA became possible (Herth et al., 
2006). EBUS-TBNA is able to sample stations that may be difficult to reach by 
mediastinoscopy, such as hilar nodes and posterior carinal nodes (Wong et al., 2007). EBUS-
TBNA is usually performed under local anaesthesia and conscious sedation using 
midazolam. TBNA is performed by direct transducer contact with the wall of the trachea or 
bronchus. When a lesion is outlined, a 22-gauge full-length steel needle is introduced 
through the biopsy channel of the endoscope. Power Doppler examination may be 
performed before the biopsy to avoid unintended puncture of vessels. Under real-time 
ultrasonic guidance, the needle is placed in the lesion. Suction is applied with a syringe, and 
the needle is moved back and forth inside the lesion (Herth et al., 2006). Three to five passes 
in each location are recommended (Tremblay et al., 2009).  
The diagnostic yield of EBUS-TBNA ranges from 83 % to 96 % (Wong et al., 2007; Garwood 
et al., 2007; Tremblay et al., 2009). The diagnostic yield significantly increased following the 
interpretation of the specimens by cytopathologist with expertise in lung disease for both 
standard and EBUS-guided TBNA (Tremblay et al., 2009).  
Both conventional and EBUS-guided TBNA are safe procedures with rare complications,  
reported as pneumothorax, pneumomediastinum, haemomediastinum, bacteraemia and 
pericarditis (Herth et al., 2006; Wong et al., 2007; Garwood et al., 2007; Tremblay et al., 2009; 
Varela-Lema et al., 2009; Tournoy et al., 2010). 
5.3 Endosonography guided needle aspiration biopsy 
Initially designed for the staging of gastrointestinal malignancies, transoesophageal 
ultrasound-guided fine needle aspiration (EUS-FNA) has proven to be an accurate 
diagnostic method for the diagnosis and staging of lung cancer and the assessment of 
sarcoidosis. Lymph nodes in the following areas can be detected by EUS: paratracheally to 
the left (station 4L); the aortopulmonary window (station 5); lateral to the aorta (station 6); in 
the subcarinal space (station 7); adjacent to the lower oesophagus (station 8); and near the 
pulmonary ligament (station 9) (Herth et al., 2006). Usually, EUS-FNA is incapable of 
reaching lymph nodes located in the anterior mediastinum and the rest of the thorax beyond 
the mediastinum (Wong et al., 2007).  
EUS-FNA is usually performed under local anaesthesia and conscious sedation using 
midazolam. The echo-endoscope is initially introduced up to the level of the coeliac axis and 
gradually withdrawn upwards for a detailed mediastinal imaging. Since the ultrasound 
waves are emitted parallel to the long axis of the endoscope, the entire needle can be 
visualised approaching a target in the sector-shaped sound field. Pulse and color Doppler 
ultrasonography imaging can be performed in cases of suspected vascular structures. For 
the aspirations, 22-gauge needles are standard, although smaller (25-gauge) and larger 
needles (19-gauge) can be used as well (Herth et al., 2006). 
The diagnostic yield of EUS-FNA is of about 80 % (Annema et al., 2005), sensitivity of 89-100 
% and specificity of 94-96 % (Fritscher-Ravens et al., 2000; Wildi et al., 2004).  
EUS-FNA is a safe procedure with rare complications (Wildi et al., 2004; Annema et al., 
2005). 
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It should be noted that the presence of non-necrotizing epitelioid granulomas in the 
specimens of the lymph nodes is not diagnostic per se for sarcoidosis. Specificity of the non-
necrotizing epitelioid granulomas depends on prevalence of sarcoidosis and other 
granulomatous disorders (such as tuberculosis) in a specific geographic region.  
6. Mediastinoscopy 
Mediastinoscopy is a common procedure used for the diagnosis of thoracic disease and the 
staging of lung cancer. Since its introduction by Carlens in 1959, mediastinoscopy has 
become the standard to which all other methods of evaluating the mediastinum are 
compared (Hammound et al., 1999). Mediastinoscopy is effective in assessment of the 
mediastinum. Porte et al. have found that sensitivity of the mediastinoscopy was 97 % in 400 
mediastinoscopes performed in 398 patients with undiagnosed mediastinal lesions (Porte et 
al., 1998). It is important to remember that non-necrotizing epithelioid cell granulomas may 
be related to carcinoma of the lung and other malignant disease. Sarcoid reactions in 
malignant disease appear in close association with tumors, in regional lymph nodes, or in 
more distant locations. They have been reported to occur in a variety of malignant diseases, 
with particularly high incidences in lymphoproliferative disorders (Laurberg, 1975; 
Brincker, 1986; Segawa et al., 1996; Tomimaru et al., 2007). 
Mediastinoscopy is more invasive diagnostic method for sampling of the mediastinal lymp 
nodes comparing with transbronchial or transoesophageal ultrasound-guided fine needle 
aspiration. Carried out under general anaesthesia, it is costly, requires in-patient care 
(Hammound et al., 1999). Although, mediastinoscopy is a safe procedure (Venissac et al., 
2003; Karfis et al., 2008), death related to mediastinoscopy is described in medical literature 
(Lemaire et al., 2006). 
7. Diagnostic approach in suspected sarcoidosis 
Presentation of sarcoidosis varied in clinical and radiological patterns. Moreover, 
comparative epidemiological studies have demonstrated that geographic, ethnic, and 
genetic factors are linked to the specific clinical characteristics of sarcoid patients 
(Baughman et al., 2001; Hosoda et al., 2002; Thomas & Hunninghake, 2003). Specificity of 
the diagnostic findings depends on other dominant diseases (e.g. tuberculosis, extrinsic 
allergic alveolitis, histoplasmosis) in specific population or a geographic region (Greco et al., 
2005; Sibille et al., 2011). Availability of specific diagnostic techniques and patients’ 
insurance policy differ in different countries. Thus, diagnostic pathway, which leads to 
confirmation of sarcoidosis, may be different.  
Pathognomonic criteria or diagnostic “gold standard” are absent (Muller-Quernheim, 1998; 
Baughman & Iannuzzi, 2000). Most authorities thus include several clinical, radiological, 
immunological and histological features into their diagnostic criteria since other disease 
processes can simulate sarcoidosis in many ways (Muller-Quernheim, 1998; Hunninghake et 
al., 1999). 
In principle, diagnosis of sarcoidosis may be based on typical clinical picture (symptoms of 
acute sarcoidosis) and typical radiological picture (Costabel, 2001; Iannuzzi et al., 2007). For 
the patients with no symptoms, bilateral hilar lymphadenopathy, and no other worrisome 
findings, close clinical observation may be sufficient (Reich et al., 1998; Kvale, 2003; Thomas 
& Hunninghake, 2003; Reich, 2010). 
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Diagnosis of sarcoidosis may be based on BAL findings (Costabel, 2001; Nunes et al., 2005). 
In patients with uncertain diagnosis after clinical assessment and high resolution computed 
tomography scanning, typical BAL cellular profiles may allow a diagnosis of sarcoidosis to 
be established with greater confidence (Wells et al., 2008).   
In author’s institution fibreoptic bronchoscopy and bronchoalveolar lavage are the first 
diagnostic procedures following clinical and radiological examination of the patient. 
Additional to BAL we perform endobronchial biopsy if bronchial mucosa seems abnormal. 
Examination of BAL fluid always includes microscopy and cultures for tuberculosis. 
Routinely, biopsy material is stained for acid-fast bacteria as well. Typical BAL fluid cellular 
or findings of non-necrotizing epitelioid granulomas in endobronchial biopsy material 
confirmed diagnosis of sarcoidosis in asymptomatic patients and patients with acute 
symptoms (Löfgren’s syndrome). At least 60 % of all sarcoidosis cases are diagnosed this 
way. If BAL fluid cellular profile is non-typical and non-necrotizing epitelioid granulomas 
are not found, bronchoscopic forceps lung biopsy is performed. Finding of non-necrotizing 
granulomas confirms sarcoidosis. Practically, mediastinoscopy is performed only in 
exceptional cases when in patients with mediastinal lymphadenopathy the diagnosis was 
not confirmed by less invasive method. Routinely the 3-6 moths follow-up of our patients 
lasts at least up to 3 years or longer if necessary.      
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families. Sarcoidosis most commonly develops in people between 20 and 50 years of age. African Americans
are somewhat more likely to develop sarcoidosis than Caucasians, and females are somewhat more likely to
develop sarcoidosis than males. The symptoms of sarcoidosis depend on the organ involved. This book deals
with the diagnosis and treatment of this mysterious disease of unknown etiology.
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